CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 5,000 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 5,000 shares of CG Oncology stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $40.09, for a total transaction of $200,450.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

CG Oncology Stock Down 0.1%

NASDAQ CGON opened at $39.82 on Friday. The company has a market capitalization of $3.04 billion, a P/E ratio of -22.50 and a beta of 1.31. CG Oncology, Inc. has a 12-month low of $14.80 and a 12-month high of $40.65. The firm has a 50-day moving average price of $30.60 and a two-hundred day moving average price of $26.74.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.05). CG Oncology had a negative net margin of 15,945.17% and a negative return on equity of 19.37%. Equities analysts expect that CG Oncology, Inc. will post -1.31 EPS for the current year.

Institutional Trading of CG Oncology

A number of hedge funds have recently added to or reduced their stakes in CGON. Winthrop Capital Management LLC acquired a new stake in CG Oncology in the second quarter valued at approximately $38,000. CWM LLC boosted its position in CG Oncology by 3,957.7% in the first quarter. CWM LLC now owns 2,110 shares of the company’s stock valued at $52,000 after buying an additional 2,058 shares in the last quarter. GAMMA Investing LLC boosted its position in CG Oncology by 1,051.0% in the first quarter. GAMMA Investing LLC now owns 2,302 shares of the company’s stock valued at $56,000 after buying an additional 2,102 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in CG Oncology by 15.6% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock valued at $77,000 after buying an additional 398 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in CG Oncology by 15.2% in the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after buying an additional 433 shares in the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CGON. Wall Street Zen raised shares of CG Oncology from a “sell” rating to a “hold” rating in a report on Friday. Piper Sandler began coverage on shares of CG Oncology in a report on Monday, August 18th. They issued an “overweight” rating and a $55.00 price objective for the company. The Goldman Sachs Group raised shares of CG Oncology to a “strong-buy” rating and set a $40.00 price objective for the company in a report on Thursday, July 10th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of CG Oncology in a report on Monday, September 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $75.00 price target on shares of CG Oncology in a report on Monday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $56.55.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.